Back

Catheter ablation for atrial fibrillation in patients with cardiac amyloidosis - Clinical characteristics and outcomes

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation nonmodifiable risk factors Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mrs Maru Mronz

Heart Center at the University of Cologne, Cologne (Germany)

5 More presentations in this session

Presentation thumbnail
Creating a pipeline to extract genetic variants associated with atrial fibrillation to use in large, multi-ethnic management registries
Ms E. Dave (Downers Grove, US)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation in adults under 40 years: clinical profile, management strategies, and long-term outcomes after catheter ablation
Doctor A. Bakytzhanuly (Astana, KZ)
Abstract Slides Video
Presentation thumbnail
Impact of atrial fibrillation on the prevalence and characteristics of cytopenia and clonal cytopenia of undetermined significance
Ms C. Forner (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation burden according to genetic risk: a secondary analysis of the randomised LOOP study
Mr J. Baadsgaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Sex differences after atrial fibrillation ablation: a patient level meta-analysis
Mr L. Barbosa (Belo Horizonte, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation nonmodifiable risk factors

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Management of arrhythmias in cardiac amyloidosis
thumbnail
Congress Presentation
Bi-atrial substrate characterization in cardiac amyloidosis: a comparative analysis of AL and ATTR forms and implications for ablation of atrial fibrillation
thumbnail
Congress Presentation
Trends in prevalence and clinical outcomes of patients with atrial fibrillation and cardiac amyloidosis- from a nationwide registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources